Breye Therapeutics Raises €67.5M Series A for Oral Retinal-Disease Therapy
Breye Therapeutics raised an oversubscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into Phase II.
TL;DR: Breye Therapeutics announced an oversubscribed €67.5 million Series A on September 29, 2026, co-led by Mission BioCapital and Novo Holdings.
Canonical company profile: Breye Therapeutics.
The round
Sound Bioventures and several new investors also participated.
The financing is intended to move Breye's lead oral asset, danegaptide, into a Phase II study for non-proliferative diabetic retinopathy.
Why the modality is notable
Many retinal diseases are treated with injections into or around the eye.
Breye is pursuing oral therapies, which could change treatment convenience if efficacy and safety hold up in later trials.
That makes the clinical development risk very different from a software startup despite the similar Series A label.
Funding history
Breye emerged from stealth in 2022 with a €4 million seed financing led by Novo Holdings and Sound Bioventures.
The 2026 Series A is therefore a substantial step-up in capital as the company moves deeper into clinical development.
What to watch
The next value-creating milestones are Phase II enrollment, efficacy readouts, safety data and whether danegaptide can show a clinically meaningful advantage in an oral format.
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
